HCP Resource Center
Today, our understanding of the role of genetic factors in heart disease is rapidly increasing and creating an opportunity for more targeted treatments aimed at the underlying cause of a given condition. At Tenaya, we are solely focused on developing new treatments for heart disease by leveraging genetic insights. Partnering with the medical community is key to advancing potentially curative precision medicines for heart disease.
“The future isn’t written in the stars — it’s written in our genome.”
– Jennifer Doudna (Nobel Laureate, co-inventor of CRISPR)
This section of our website is intended to serve as a resource for our medical community (healthcare professionals or “HCPs”) as we collaborate to improve the lives of patients with cardiomyopathies and other heart conditions.
Resources for patients
Gene Therapy Basics
Learn more about genomic medicine for cardiomyopathies
Gene Therapy Brochure
Gene to Protein brochure
A clinical trial for individuals with MYBPC3-associated HCM.
Visit Site
A clinical trial for individuals with PKP2-associated ARVC
Visit Site
HCM Studies
Learn about HCM and its genetic causes
Visit Site
ARVC Studies
Learn about ARVC and its genetic causes
Visit Site
Connect with our team at an upcoming conference
ASGCT
Interim Data from RIDGE™-1: A Phase 1b Interventional Study to Evaluate Safety and Efficacy of TN-401, an AAV9 Investigational Gene Replacement Therapy, in Adults with PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
Presenter: Dr. John Giudicessi
Session: Late-Breaking Abstracts II
ESC Heart Failure 2026
Early experience optimizing immunosuppressive use and monitoring in MyPEAKTM-1, a first-in-human study of TN-201, an AAV9 gene replacement therapy in MYBPC3-associated hypertrophic cardiomyopathy
Presenter: Dr. Milind Desai
Session: Advanced phenotyping and risk stratification in cardiomyopathies and myocarditis